VISN 1 MIRECC Staff: Mehmet Sofuoglu, M.D., Ph.D.
Mehmet Sofuoglu, M.D., Ph.D.
Dr. Mehmet Sofuoglu received his Doctorate of Medicine in 1986 from Hacettepe University in Turkey, and he received his Ph.D. in Pharmacology from the University of Minnesota in 1991. He completed his residency in psychiatry at the University of Minnesota and Stanford University in 1995. He has been a MIRECC Investigator since 2001. In 2006, he became the Co-Director of the VISN 1 New England MIRECC and in 2012 became the Director. He is a Professor of Psychiatry at Yale University. Dr. Sofuoglu's long-term goal is to develop medications for stimulant addiction including cocaine, amphetamines, and nicotine. His research bridges the gap between human laboratory studies examining the medical safety and potential efficacy of new medications for substance dependence and outpatient trials directly examining these medications in drug relapse. Current projects include:
- A clinical trial testing the efficacy of galantamine, a cognitive enhancer, as a treatment for cocaine dependence.
- A pilot clinical trial testing the safety and efficacy of minocycline, a microglia activation inhibitor, as a treatment for hyperalgesia in opioid maintained patients.
- A human laboratory study examining the reinforcing threshold and dose-response curves for IV nicotine self-administration in male and female smokers with or without nicotine dependence.
- A human laboratory study examining the reinforcing effects of menthol in combination with IV nicotine in smokers.
- A clinical trial testing the efficacy of galantamine, a cholinesterase inhibitor, for smoking cessation.